Myocardial Infarction Therapeutics Market
Myocardial infarction, generally called as heart attack is characterized by reduced blood supply to the heart muscles, primarily due to coronary artery disease. According to American Heart Association (AHA), every year around 17.3 Mn people die of heart diseases worldwide, with myocardial infarction being the leading cause of death. In 2012, British Heart Foundation reported 73,680 deaths in United Kingdom due to coronary heart disease. Mortality from acute myocardial infarction can be decreased if patient receives the emergency access to the treatment. The global cardiovascular treatment market generated a revenue of 170 Bn in 2010 and is expected to expand drastically over the forecast period of 2016-2026. Multitude of products available for the treatment of acute myocardial infarction with different indications include Zorprin, Plavix, Angiomax, Diovan, Lovenox, Aggrastat, NitroStat, Benicar and many more.
Myocardial infarction, generally called as heart attack is characterized by reduced blood supply to the heart muscles, primarily due to coronary artery disease. According to American Heart Association (AHA), every year around 17.3 Mn people die of heart diseases worldwide, with myocardial infarction being the leading cause of death. In 2012, British Heart Foundation reported 73,680 deaths in United Kingdom due to coronary heart disease. Mortality from acute myocardial infarction can be decreased if patient receives the emergency access to the treatment. The global cardiovascular treatment market generated a revenue of 170 Bn in 2010 and is expected to expand drastically over the forecast period of 2016-2026. Multitude of products available for the treatment of acute myocardial infarction with different indications include Zorprin, Plavix, Angiomax, Diovan, Lovenox, Aggrastat, NitroStat, Benicar and many more.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Report Description<br />
• Hospital Pharmacies<br />
• Drug Stores<br />
• Online drug stores<br />
<strong>Myocardial</strong> <strong>Infarction</strong> <strong>Therapeutics</strong> <strong>Market</strong>: Overview<br />
Analgesics and antiplatelet agents’ segments are foreseen to hold more share in global<br />
myocardial infarction therapeutics market as these agents are used for initial treatment<br />
of an acute myocardial infarction. Amongst sales channels, hospital pharmacy segment is<br />
expected to contribute more into global myocardial infarction therapeutics market. The<br />
global myocardial infarction therapeutics market is foreseen to experience the boost in<br />
market volume over the forecast period due to the launch of several new products such<br />
as Apixaban, Xarelto and introduction of generic drugs after expiration of patents for<br />
Crestor and Benicar.<br />
Request for TOC: http://www.futuremarketinsights.com/toc/rep-gb-1263<br />
<strong>Myocardial</strong> <strong>Infarction</strong> <strong>Therapeutics</strong> <strong>Market</strong>: Regional Overview<br />
Geographically, the global myocardial infarction terapeutic market is classified into<br />
regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-<br />
Pacific, Japan, Middle East and Africa. North America will continue to take leading<br />
position in global myocardial infarction therapeutic market owing to expanding aging<br />
population and prevalence of co-morbidities.
Change language